all clinics in california

Clinical Trials / Drug Trials News From Medical News Today
Latest Health News and Medical News posted throughout the day, every day.

ACT Files Documentation With FDA For Clinical Trials Using ES Cells To Treat ...

29 Jul 2010 at 2:00pm
Advanced Cell Technology, Inc...

Etubics Enters Phase I Cancer Clinical Trials Focused On Colorectal Cancer

29 Jul 2010 at 10:00am
Etubics Corporation, a biopharmaceutical company developing "next generation" vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S...

Advaxis Phase I Survival Update

29 Jul 2010 at 8:00am
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy...

New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE ...

29 Jul 2010 at 4:00am
Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)...

Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA N...

29 Jul 2010 at 4:00am
Teva Respiratory announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial Of PSI-9...

29 Jul 2010 at 4:00am
Pharmasset, Inc. (Nasdaq: VRUS) announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection...

Angiotech Pharmaceuticals And Partner Athersys Announce Positive Results From...

29 Jul 2010 at 4:00am
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack...

Curemark Opens Autism Trials At New Jersey Site

29 Jul 2010 at 4:00am
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment. Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia...

Global Breakthrough In Treatment Of Dementia 'Within Reach' - Clinical Trial ...

29 Jul 2010 at 3:00am
A Glasgow-based medical research company is leading a worldwide sleep study which could radically reduce the symptoms associated with dementia. The groundbreaking trial, conducted by CPS Research, is the first of its kind to investigate the use of sleep hormone melatonin as an add on treatment for dementia. The study is already showing remarkable initial results in volunteers from Scotland...

Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Re...

28 Jul 2010 at 2:00pm
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States...

NYU Langone Begins Clinical Trial Offering Vascular-Targeted Photodynamic The...

28 Jul 2010 at 4:00am
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells...

Omeros Enrolls First Patient In Phase 2b Clinical Trial Evaluating OMS302 In ...

28 Jul 2010 at 4:00am
Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has enrolled the first patient in its Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery...

CMS Approves Clinical Study Of Genetic Test To Predict Patient Response To Le...

28 Jul 2010 at 3:00am
Iverson Genetic Diagnostics announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data...

Parntership Will Speed Up Time Between Research And Clinical Trials

28 Jul 2010 at 2:00am
A major research company affiliated with the University of Colorado with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient...

Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase ...

27 Jul 2010 at 3:00am
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma...

All Clinics in california